“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program…”
News Archive
Bonum Therapeutics to Present Lead Program at AACR
“We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”
IL-2 Program with Bonum’s Drs. John Mulligan and Neela Patel
Business of Biotech
Dec 20, 2023
Podcast
Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent
The Bio Report
Aug 20, 2023
Podcast